Clinical trial inclusion in patients with relapsed/refractory neuroblastoma following the European Precision Cancer Medicine trial MAPPYACTS.

MLA

Chaix, Jordane, et al. “Clinical Trial Inclusion in Patients with Relapsed/Refractory Neuroblastoma Following the European Precision Cancer Medicine Trial MAPPYACTS.” European Journal of Cancer (Oxford, England : 1990), vol. 201, Apr. 2024, p. 113923. EBSCOhost, https://doi.org/10.1016/j.ejca.2024.113923.

APA

Chaix, J., Schleiermacher, G., Corradini, N., André, N., Thebaud, E., Gambart, M., Defachelles, A.-S., Entz-Werle, N., Chastagner, P., De Carli, É., Ducassou, S., Landman-Parker, J., Adam-de-Beaumais, T., Larive, A., Michiels, S., Vassal, G., Valteau-Couanet, D., Geoerger, B., & Berlanga, P. (2024). Clinical trial inclusion in patients with relapsed/refractory neuroblastoma following the European Precision Cancer Medicine trial MAPPYACTS. European Journal of Cancer (Oxford, England : 1990), 201, 113923. https://doi.org/10.1016/j.ejca.2024.113923

Chicago

Chaix, Jordane, Gudrun Schleiermacher, Nadège Corradini, Nicolas André, Estelle Thebaud, Marion Gambart, Anne-Sophie Defachelles, et al. 2024. “Clinical Trial Inclusion in Patients with Relapsed/Refractory Neuroblastoma Following the European Precision Cancer Medicine Trial MAPPYACTS.” European Journal of Cancer (Oxford, England : 1990) 201 (April): 113923. doi:10.1016/j.ejca.2024.113923.